Table 1. Comparison of clinical characteristics between benign and adenocarcinoma patient groups.
| Clinical characteristics | Benign (n=21) | Adenocarcinoma (n=149) | P value |
|---|---|---|---|
| Age (years) | 57.8±10.9 | 61.1±8.9 | 0.115 |
| Sex | 0.012* | ||
| Female | 9 (42.9) | 105 (70.5) | |
| Male | 12 (57.1) | 44 (29.5) | |
| Smoking history | 7 (33.3) | 26 (17.4) | 0.085 |
| Fasting blood-glucose (mmol/L) | 6.6±1.9 | 6.7±1.7 | 0.825 |
| Multifocality | 4 (19.0) | 53 (35.6) | 0.133 |
| GGN number | 1.0 (1.0–1.0) | 1.0 (1.0–3.0) | 0.586 |
| CEA (ng/mL) | 1.9 (1.1–2.6) | 1.8 (1.2–2.8) | 0.603 |
| CYFRA21-1 (ng/mL) | 2.2 (1.7–2.7) | 2.2 (1.8–2.9) | 0.356 |
| CA199 (U/mL) | 9.1 (6.5–14.0) | 9.0 (5.4–12.5) | 0.959 |
| NSE (ng/mL) | 12.5 (10.9–17.1) | 13.7 (11.6–17.1) | 0.829 |
| SCCAg (ng/mL) | 0.9 (0.7–1.1) | 0.7 (0.5–1.0) | 0.136 |
Data were presented as mean ± SD/P50 (P25–P75)/N (%). *, P<0.05. Normal range of tumor markers: CEA: 0–5 ng/mL, CYFRA21-1: 0–3.3 ng/mL, CA199: 0–37 U/mL, NSE: 0–17 ng/mL, SCCAg: 0–1.5 ng/mL. GGN, ground-glass nodule; CEA, carcinoembryonic antigen; CYFRA21-1, cytokeratin 19 fragments; CA199, carbohydrate antigen 199; NSE, neonatal status epilepticus; SCCAg, squamous cell carcinoma antigen.